This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT01496573
First received: December 16, 2011
Last updated: May 17, 2016
Last verified: May 2016
December 16, 2011
May 17, 2016
December 2011
May 2016   (Final data collection date for primary outcome measure)
CRKL expression at the protein level [ Time Frame: 1 month ]
CRKL expression at the protein level
Complete list of historical versions of study NCT01496573 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma
Observational - CRKL Expression at the Protein Level in Rhabdomyosarcoma Tumors by Tissue Microarray (TMA)
This research trial studies biomarkers in tumor tissue samples from younger patients with rhabdomyosarcoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer

PRIMARY OBJECTIVES:

I. To demonstrate CRKL expression at the protein level in rhabdomyosarcoma tumors by tissue microarray (TMA).

OUTLINE:

Archived tumor tissue samples are analyzed for CRKL expression.

Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Retention:   Samples With DNA
Description:
tumor tissue
Non-Probability Sample
Alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma
  • Alveolar Childhood Rhabdomyosarcoma
  • Childhood Rhabdomyosarcoma
  • Embryonal Childhood Rhabdomyosarcoma
Other: laboratory biomarker analysis
Correlative studies
Basic science (biomarker analysis)
Archived tumor tissue samples are analyzed for CRKL expression.
Intervention: Other: laboratory biomarker analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
77
May 2016
May 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma specimens from the Children Oncology Group (COG) tumor microarrays (TMAs)
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01496573
ARST12B4
NCI-2012-00094 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
No
Not Provided
Not Provided
Not Provided
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Lee Helman, MD Children's Oncology Group
Children's Oncology Group
May 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP